MDMA therapy gets support from prominent research group as FDA weighs action

As an August deadline for the U.S. Food and Drug Administration looms regarding approval for psychedelic therapies, a coalition of well-known scientific researchers took it upon itself to publicize its support for midomafetamine (MDMA)-based treatment for patients with post-traumatic stress disorder. In an online consensus statement, 23 medical doctors and …